亚太地区急性肺损伤市场预测至 2028 年 - COVID-19 影响及按治疗（机械通气、液体管理、药物治疗和辅助手术）和最终用户（医院、门诊手术中心等）进行的区域分析
市场介绍
根据中国、日本、印度、澳大利亚、韩国等国家/地区分析亚太地区急性肺损伤市场亚太地区其他地区。 2021年，中国占据了最大的市场份额。该国市场的增长归因于呼吸道疾病和其他各种肺部疾病的患病率较高。中国是世界上人口最多的国家之一，也是呼吸系统疾病患者数量最多的国家。该国的老年人口也显着增加；因此，肺部相关疾病是老年人死亡的主要原因。根据最近的一项研究《中国的慢性病与老龄化》，中国人口正在老龄化，慢性病日益流行。预计从2010年到2040年，中国60岁以上人口比例将从12.4%（1.68亿）上升到28%（4.02亿）。在中国，大约80%的60岁老年人死亡是死于慢性非传染性疾病（NCD）；最常见的疾病是缺血性心脏病、慢性阻塞性肺病 (COPD)、中风和 2 型糖尿病。行为风险，包括吸烟、久坐行为、饮酒和不良饮食摄入，对这些病症有显着影响。鉴于该地区慢性病发病率逐渐上升，中国对先进治疗的需求不断增加。这一因素极大地促进了急性肺损伤疗法的采用。因此，上述因素的集体影响预计将促进该地区市场的增长。
就 COVID-19 而言，亚太地区受到严重影响，特别是印度。根据联合国人道主义事务协调办公室 (UNOCHA) 的数据，截至 2021 年 9 月，亚太地区的 COVID-19 病例达到 5650 万例。 COVID-19感染一直是急性肺损伤患者面临的严重问题。根据亚洲感染患者的临床数据，肺水肿的放射学证据很常见，值得临床关注。肺水肿是急性肺损伤（ALI）的一种表现，可能进展为低氧血症和潜在的急性呼吸窘迫综合征（ARDS）。诊断为 ARDS 和 ALI 的患者预后较差，死亡率可能较高。尽管没有正式批准针对 COVID-19 感染的有效治疗方法，但通常需要氧疗支持通气，有时还需要机械通气。全身和/或局部糖皮质激素治疗可能有助于减轻肺部炎症和水肿，从而减少 ARDS 的发展和/或后果。例如，一项综合中国和意大利数据的研究表明，27% 的高度感染的 COVID-19 患者需要辅助通气，死亡率为 21%。因此，由于 COVID-19 的影响，该地区的急性肺损伤市场出现了大幅扩张。
市场概况和动态
亚太地区急性肺损伤市场预计将从2021年的1.2216亿美元增长到2028年的1.7461亿美元；预计 2021 年至 2028 年复合年增长率为 5.2%。呼吸系统疾病的高患病率与老年人口上呼吸道管腔尺寸的减小有关。肺部疾病是该地区最常见的疾病之一。人们患有各种呼吸系统疾病。吸烟、感染和遗传因素是导致呼吸系统疾病的常见因素。慢性阻塞性肺病、哮喘、慢性支气管炎、囊性纤维化和肺癌等疾病是重大的公共卫生负担。此外，世界卫生组织（WHO）指出，每年有数百万人死于肺癌，使其成为最常见的致命传染病。此外，根据世界卫生组织的建议，91%的人口居住在空气质量不佳的城市和地区。患有这些呼吸系统疾病的患者通常会出现呼吸困难。与急性肺损伤相关的呼吸衰竭或急性呼吸窘迫综合征（ARDS）是导致术后死亡的最关键因素之一。此外，州和地方卫生部门以及其他临床和公共卫生伙伴继续监测吸烟电子烟或电子烟产品使用相关肺损伤（EVALI）。因此，所有上述因素预计将导致亚太地区急性肺损伤市场在预测期内的增长。
关键细分市场
在治疗方面，机械通气细分市场在2020年亚太地区急性肺损伤市场中占据最大份额。在最终用户方面，医院细分市场在亚太地区急性肺损伤市场中占有较大份额。 2020年肺损伤市场。
主要来源和上市公司
一些主要的一手和二手来源准备本亚太地区急性肺损伤市场报告所参考的资料包括公司网站、年度报告、财务报告、国家政府文件和统计数据库等。报告中列出的主要公司有Angion；葛兰素史克公司； ReAlta 生命科学公司； Stemedica 细胞技术公司；和 Windtree Therapeutics, Inc。
购买报告的理由
- 了解亚太地区急性肺损伤市场格局，并确定最有可能保证强劲回报的细分市场
- 了解亚太地区急性肺损伤不断变化的竞争格局，保持领先地位市场
- 通过确定最有可能销售前景的细分市场，有效规划亚太地区急性肺损伤市场的并购和合作伙伴关系
- 通过对市场的洞察力和全面分析，帮助做出明智的业务决策亚太地区急性肺损伤市场各个细分市场的市场表现
- 获取亚太地区2021-2028年各个细分市场的市场收入预测。
亚太地区急性肺损伤市场细分
亚太地区急性肺损伤市场 - 按治疗划分
- 机械通气
- 液体管理
- 药物治疗
- 辅助治疗
亚太地区急性肺损伤市场 - 最终用户
- 医院
- 门诊手术中心
- 其他
亚太地区急性肺损伤市场 - 按国家/地区
- 中国
- 日本
- 印度
- 澳大利亚
- 韩国
- 亚太地区其他地区
亚太地区急性肺损伤市场 - 公司简介
< ul>TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 APAC Acute Lung Injury Market – By Therapy
1.3.2 APAC Acute Lung Injury Market – By End User
1.3.3 APAC Acute Lung Injury Market– By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. APAC Acute Lung Injury Market– Market Landscape
4.1 Overview
4.2 APAC PEST Analysis
4.3 Experts Opinion
5. APAC Acute Lung Injury Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Respiratory Diseases
5.1.2 Rising Geriatric Population
5.2 Market Restraints
5.2.1 High Cost of Therapies
5.3 Market Opportunities
5.3.1 Technological Advancements by Market Players
5.4 Future Trends
5.4.1 Growing Pipeline Drugs
5.5 Impact Analysis
6. Acute Lung Injury Market– APAC Analysis
6.1 APAC Acute Lung Injury Market Revenue Forecast and Analysis
7. APAC Acute Lung Injury Market Analysis – By Therapy
7.1 Overview
7.2 APAC Acute Lung Injury Market Revenue Share, by Therapy (2021 and 2028)
7.3 Mechanical Ventilation
7.3.1 Overview
7.3.2 Mechanical Ventilation: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Fluid Management
7.4.1 Overview
7.4.2 Fluid Management: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Pharmacotherapy
7.5.1 Overview
7.5.2 Pharmacotherapy: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Adjunctive Procedures
7.6.1 Overview
7.6.2 Adjunctive Procedures: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
8. APAC Acute Lung Injury Market Analysis – By End User
8.1 Overview
8.2 APAC Acute Lung Injury Market Revenue Share, by End User (2021 and 2028)
8.3 Hospitals
8.3.1 Overview
8.3.2 Hospitals: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Ambulatory Surgery Centers
8.4.1 Overview
8.4.2 Ambulatory Surgery Centers: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
9. APAC Acute Lung Injury Market – Country Analysis
9.1 APAC: Acute Lung Injury Market
9.1.1 Overview
9.1.2 APAC: Acute Lung Injury Market, by Country, 2021 & 2028 (%)
9.1.2.1 China: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.1.1 China: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.1.2 China: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)
9.1.2.1.3 China: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)
9.1.2.2 Japan: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.2.1 Japan: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.2.2 Japan: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)
9.1.2.2.3 Japan: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)
9.1.2.3 India: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.3.1 India: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.3.2 India: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)
9.1.2.3.3 India: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)
9.1.2.4 South Korea: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.4.1 South Korea: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.4.2 South Korea: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)
9.1.2.4.3 South Korea: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)
9.1.2.5 Australia: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.5.1 Australia: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.5.2 Australia: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)
9.1.2.5.3 Australia: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)
9.1.2.6 Rest of APAC: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.6.1 Rest of APAC: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.6.2 Rest of APAC: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)
9.1.2.6.3 Rest of APAC: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)
10. Impact Of COVID-19 Pandemic on APAC Acute Lung Injury Market
10.1 APAC: Impact Assessment of COVID-19 Pandemic
11. Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 GlaxoSmithKline Plc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Stemedica Cell Technologies, Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Windtree Therapeutics, Inc.
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 ReAlta Life Sciences, Inc.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Angion
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. APAC Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
Table 2. China: Acute Lung Injury Market, by Therapy– Revenue and Forecast to 2028 (USD Million)
Table 3. China: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 4. Japan: Acute Lung Injury Market, by Therapy– Revenue and Forecast to 2028 (USD Million)
Table 5. Japan: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 6. India: Acute Lung Injury Market, by Therapy– Revenue and Forecast to 2028 (USD Million)
Table 7. India: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 8. South Korea: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)
Table 9. South Korea: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 10. Australia: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)
Table 11. Australia: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 12. Rest of APAC: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)
Table 13. Rest of APAC: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 14. Organic Developments Done by Companies
Table 15. Inorganic Developments Done by Companies
Table 16. Glossary of Terms
LIST OF FIGURES
Figure 1. APAC Acute Lung Injury Market Segmentation
Figure 2. APAC Acute Lung Injury Market Segmentation, By Country
Figure 3. APAC Acute Lung Injury Market Overview
Figure 4. Mechanical Ventilation Segment Held the Largest Share of the Market in 2021
Figure 5. India to Show Significant Growth During Forecast Period
Figure 6. APAC PEST Analysis
Figure 7. APAC Acute Lung Injury Market Impact Analysis of Driver and Restraints
Figure 8. APAC Acute Lung Injury Market– Revenue Forecast and Analysis
Figure 9. APAC Acute Lung Injury Market Revenue Share, by Therapy (2021 and 2028)
Figure 10. APAC Mechanical Ventilation: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
Figure 11. APAC Fluid Management: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. APAC Pharmacotherapy: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. APAC Adjunctive Procedures: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. APAC Acute Lung Injury Market Revenue Share, by End User (2021 and 2028)
Figure 15. APAC Hospitals: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. APAC Ambulatory Surgery Centers: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. APAC Others: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. APAC: Acute Lung Injury Market, by Key Country – Revenue (2021) (USD Million)
Figure 19. APAC: Acute Lung Injury Market, by Country, 2021 & 2028 (%)
Figure 20. China: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
Figure 21. Japan: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
Figure 22. India: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
Figure 23. South Korea: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
Figure 24. Australia: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
Figure 25. Rest of APAC: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
Figure 26. Impact of COVID-19 Pandemic on APAC Country Markets
- Angion
- GlaxoSmithKline Plc
- ReAlta Life Sciences, Inc.
- Stemedica Cell Technologies, Inc
- Windtree Therapeutics, Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the APAC acute lung injury market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the APAC acute lung injury market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth APAC market trends and outlook coupled with the factors driving the acute lung injury market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution